Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

CAR-T Cell Therapy for Acquired Hemophilia A

Blood (2024) 144 (Supplement 1): 5503.

https://doi.org/10.1182/blood-2024-202970

Published: 2024

Journal Articles

Sustained Improvement of Survival in Patients Receiving Emicizumab Prophylaxis Instead of Immunosuppression during Early Management of Acquired Hemophilia a (AHA)

Inga M. Schimansky, Andreas Tiede, Christiane Dobbelstein, Dr. Robert Klamroth, Christina Hart, Ulrich J. Sachs, Richard Greil, Paul N. Knöbl, Johannes Oldenburg, Christian Pfrepper, Karolin Trautmann-Grill, Patrick Moehnle, Katharina Holstein, Wolfgang A. Miesbach

Blood (2024) 144 (Supplement 1): 555.

https://doi.org/10.1182/blood-2024-205490

Published: 2024

Journal Articles

Emicizumab Versus Immunosuppression for Acquired Hemophilia Α (AHA)

Christina Hart, Robert Klamroth, Ulrich J. Sachs, Richard Greil, Paul N. Knoebl, Johannes Oldenburg, Wolfgang Miesbach, Christian Pfrepper, Karolin Trautmann-Grill, Isabell Pekrul, Katharina Holstein, Hermann Eichler, Carmen Weigt, Dorothea Schipp, Sonja Werwitzke, Andreas Tiede

Blood (2023) 142 (Supplement 1): 2612.

https://doi.org/10.1182/blood-2023-174958

Published: 2023

Journal Articles

Matching Adjusted Indirect Comparisons of Personalized Prophylaxis with Simoctocog Alfa Versus Efmoroctocog Alfa, Damoctocog Alfa Pegol and Rurioctocog Alfa Pegol in Patients with Hemophilia a

Craig M. Kessler, Andreas Tiede

Blood (2022) 140 (Supplement 1): 2755–2756.

https://doi.org/10.1182/blood-2022-162205

Published: 2022

Journal Articles

Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results

Frank W. G. Leebeek, Flora Peyvandi, Miguel Escobar, Andreas Tiede, Giancarlo Castaman, Michael Wang, Tung Wynn, Jovanna Baptista, Yi Wang, Jingmei Zhang, Björn Mellgård, Gülden Özen

Blood (2022) 140 (2): 89–98.

https://doi.org/10.1182/blood.2021014810

Published: 2022

Includes: Supplemental data

Journal Articles

Vaccine-Induced Thrombocytopenia and Thrombosis (VITT) Antibodies Recognize Neutrophil-Activating Peptide 2 (NAP2) As Well As Platelet Factor 4 (PF4): Mechanistic and Clinical Implications

Lubica Rauova, Andy Wang, Serge Yarovoi, Sanjay Khandelwal, Anand Padmanabhan, Olga Oleshko, Matthew J. Charman, Andreas Tiede, Charles S. Abrams, Matthew D. Weitzman, Gowthami M. Arepally, Douglas B. Cines, Mortimer Poncz

Blood (2021) 138 (Supplement 1): 292.

https://doi.org/10.1182/blood-2021-151685

Published: 2021

Journal Articles

Prothrombotic immune thrombocytopenia after COVID-19 vaccination

Andreas Tiede, Ulrich J. Sachs, Andreas Czwalinna, Sonja Werwitzke, Rolf Bikker, Joachim K. Krauss, Frank Donnerstag, Karin Weißenborn, Günter Höglinger, Benjamin Maasoumy, Heiner Wedemeyer, Arnold Ganser

Blood (2021) 138 (4): 350–353.

https://doi.org/10.1182/blood.2021011958

Published: 2021

Includes: Supplemental data

Journal Articles

Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice

Nadine Vollack-Hesse, Olga Oleshko, Sonja Werwitzke, Barbara Solecka-Witulska, Christoph Kannicht, Andreas Tiede

Blood (2021) 137 (8): 1072–1081.

https://doi.org/10.1182/blood.2020006468

Published: 2021

Includes: Supplemental data

Journal Articles

Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Damoctocog Alfa Pegol (BAY 94-9027) and Efmoroctocog Alfa (rFVIIIFc) in Patients with Severe Hemophilia A

Alexander Solms, Anita Shah, Sara Wiegmann, Maurice Ahsman, Erik Berntorp, Andreas Tiede, MD, Alfonso Iorio, MDPhD, Maria Elisa Mancuso, Tihomir Zhivkov, Toshko Lissitchkov

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-136586

Published: 2020

Journal Articles

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study

Katharina Holstein, Xiaofei Liu, Andrea Smith, Paul Knöbl, Robert Klamroth, Ulrich Geisen, Hermann Eichler, Wolfgang Miesbach, Andreas Tiede

Blood (2020) 136 (3): 279–287.

https://doi.org/10.1182/blood.2019003639

Published: 2020

Includes: Supplemental data

Journal Articles

A New Dosing Model Based on Body Mass Index to Guide Factor VIII Dosing in Patients with Hemophilia A

Andreas Tiede, MD, Georg Goldmann, Predrag S Miljić, Lars Korsholm, Irina Matytsina, Paula Persson, Toshko Jelev Lissitchkov, MD

Blood (2018) 132 (Supplement 1): 2491.

https://doi.org/10.1182/blood-2018-99-111269

Published: 2018

Journal Articles

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Blood (2018) 132 (Supplement 1): 2465.

https://doi.org/10.1182/blood-2018-99-113996

Published: 2018

Journal Articles

Novel Von Willebrand Factor (vWF) Fragment Supports Subcutaneous Administration of Factor VIII: Pharmacokinetic Data from Hemophilia A Mouse Model

Nadine Vollack, PhD, Sonja Werwitzke, MD PhD, Barbara A Solecka-Witulska, PhD, Christoph Kannicht, PhD, Andreas Tiede, MD

Blood (2017) 130 (Supplement 1): 4877.

https://doi.org/10.1182/blood.V130.Suppl_1.4877.4877

Published: 2017

Journal Articles

Factor VIII Activity and Risk of Bleeding in Acquired Hemophilia a: Results from the Gth-AH 01/2010 Study

Katharina Holstein, MD, Andrea Smith, Paul Knöbl, MD PhD, Christiane Dobbelstein, MD, Wolfgang A. Miesbach, MD PhD, Michael Spannagl, MD PhD, Jürgen Heinz, MD PhD, Ute Scholz, MD, Hermann Eichler, MD, Angela Huth-Kühne, MD, Robert Klamroth, MD PhD, Armin Koch, MD PhD, Andreas Tiede, MD

Blood (2017) 130 (Supplement 1): 22.

https://doi.org/10.1182/blood.V130.Suppl_1.22.22

Published: 2017

Journal Articles

Frequency and epitope specificity of anti–factor VIII C1 domain antibodies in acquired and congenital hemophilia A

Joerg Kahle, Aleksander Orlowski, Diana Stichel, John F. Healey, Ernest T. Parker, Marc Jacquemin, Manuela Krause, Andreas Tiede, Dirk Schwabe, Pete Lollar, Christoph Königs

Blood (2017) 130 (6): 808–816.

https://doi.org/10.1182/blood-2016-11-751347

Published: 2017

Includes: Supplemental data

Journal Articles

Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

Andreas Tiede, Christoph J. Hofbauer, Sonja Werwitzke, Paul Knöbl, Saskia Gottstein, Rüdiger E. Scharf, Jürgen Heinz, Jürgen Groß, Katharina Holstein, Christiane Dobbelstein, Fritz Scheiflinger, Armin Koch, Birgit M. Reipert

Blood (2016) 127 (19): 2289–2297.

https://doi.org/10.1182/blood-2015-09-672774

Published: 2016

Includes: Supplemental data

Journal Articles

Personalized Prophylaxis with Human-Cl Recombinant FVIII in HA Patients

Robert Klamroth, Toshko Lissitchkov, MD, Luminita Rusen, Olaf Walter, MD MBA, Johann Bichler, PhD, K John Pasi, Andreas Tiede, MD PhD, Sigurd Knaub, PhD

Blood (2015) 126 (23): 547.

https://doi.org/10.1182/blood.V126.23.547.547

Published: 2015

Journal Articles

Diagnostic and Prognostic Value of Factor VIII Binding Antibodies in Acquired Hemophilia A: Data from the GTH-AH 01/2010 Study

Andreas Tiede, MD PhD, Sonja Werwitzke, MD PhD, Ulrich Geisen, MD PhD, Ulrike Nowak-Göttl, MD PhD, Hermann Eichler, MD PhD, Bernhard Stephan, MD, Ute Scholz, MD, Holstein Katharina, MD, Robert Klamroth, Paul Knöbl, MD PhD, Angela Huth-Kühne, MD, Barbara Bomke, MD

Blood (2015) 126 (23): 3515.

https://doi.org/10.1182/blood.V126.23.3515.3515

Published: 2015

Journal Articles

Frequency and Epitope Specificity of Anti-Factor VIII C1 Domain Antibodies in Acquired and Hereditary Hemophilia Inhibitor Patient Plasma

Joerg Kahle, PhD, Aleksander Orlowski, Anja Schmidt, PhD, Kerstin Brettschneider, Thomas Klingebiel, MD, John F Healey, BS, Ernest T Parker, BA, John (Pete) S Lollar, MD, Marc Jacquemin, MD, Manuela Krause, MD, Andreas Tiede, MD PhD, Dirk Schwabe, MD, Christoph Königs, MD PhD

Blood (2015) 126 (23): 3491.

https://doi.org/10.1182/blood.V126.23.3491.3491

Published: 2015

Journal Articles

Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans

Christoph J. Hofbauer, Shawn F. J. Whelan, Maria Hirschler, Peter Allacher, Frank M. Horling, John-Philip Lawo, Johannes Oldenburg, Andreas Tiede, Christoph Male, Jerzy Windyga, Andreas Greinacher, Paul N. Knöbl, Gerald Schrenk, Jadranka Koehn, Friedrich Scheiflinger, Birgit M. Reipert

Blood (2015) 125 (7): 1180–1188.

https://doi.org/10.1182/blood-2014-09-598268

Published: 2015

Includes: Supplemental data

NARROW

CAR-T Cell Therapy for Acquired Hemophilia A

Sustained Improvement of Survival in Patients Receiving Emicizumab Prophylaxis Instead of Immunosuppression during Early Management of Acquired Hemophilia a (AHA)

Emicizumab Versus Immunosuppression for Acquired Hemophilia Α (AHA)

Matching Adjusted Indirect Comparisons of Personalized Prophylaxis with Simoctocog Alfa Versus Efmoroctocog Alfa, Damoctocog Alfa Pegol and Rurioctocog Alfa Pegol in Patients with Hemophilia a

Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results

Vaccine-Induced Thrombocytopenia and Thrombosis (VITT) Antibodies Recognize Neutrophil-Activating Peptide 2 (NAP2) As Well As Platelet Factor 4 (PF4): Mechanistic and Clinical Implications

Prothrombotic immune thrombocytopenia after COVID-19 vaccination

Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice

Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Damoctocog Alfa Pegol (BAY 94-9027) and Efmoroctocog Alfa (rFVIIIFc) in Patients with Severe Hemophilia A

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study

A New Dosing Model Based on Body Mass Index to Guide Factor VIII Dosing in Patients with Hemophilia A

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Novel Von Willebrand Factor (vWF) Fragment Supports Subcutaneous Administration of Factor VIII: Pharmacokinetic Data from Hemophilia A Mouse Model

Factor VIII Activity and Risk of Bleeding in Acquired Hemophilia a: Results from the Gth-AH 01/2010 Study

Frequency and epitope specificity of anti–factor VIII C1 domain antibodies in acquired and congenital hemophilia A

Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

Personalized Prophylaxis with Human-Cl Recombinant FVIII in HA Patients

Diagnostic and Prognostic Value of Factor VIII Binding Antibodies in Acquired Hemophilia A: Data from the GTH-AH 01/2010 Study

Frequency and Epitope Specificity of Anti-Factor VIII C1 Domain Antibodies in Acquired and Hereditary Hemophilia Inhibitor Patient Plasma

Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only